Ashley McEvoy, the executive vice president of medical devices at J&J, revealed Johnson & Johnson’s intentions when she claims, “In this new era of health care, we’re aiming to simplify surgery, drive efficiency, reduce complications, and improve outcomes for patients, ultimately making surgery safer.”
In the past several years, Johnson & Johnson’s has dedicated itself to increasing its presence in the fields of surgical-robotics. In 2018, for example, Johnson & Johnson purchased Orthotaxy. Orthotaxy works to develop surgical-robotic tools which will help doctors perform partial and total knee replacements. Although its underlying technology is far different than Auris, the combination places Johnson & Johnson at the forefront of surgical-robotics innovations. Plus, Johnson & Johnson also maintains a partnership with Alphabet’s science arm, Verily, where they are developing new, improved ways to deploy robots in dangerous surgeries.
Auris gained FDA-approval for its flagship product, a robot-camera known as the Monarch, in March 2018, and it has quickly gone on the become a favorite of doctor’s across the U.S. Experts are curious to see how Johnson & Johnson deploys this product across their brand as well as how they may improve this already innovative product.
